Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018;8(21):5986-5994.

Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, et al. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018;9:2102.

Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, et al. Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018;93(11):1358-1367.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.

Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, et al. Specific F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin. J Nucl Med. 2018;59(10):1538-1543.

Massonneau J, Ouellet C, Lucien F, Dubois CM, Tyler J, Boissonneault G. Suboptimal extracellular pH values alter DNA damage response to induced double-strand breaks. FEBS Open Bio. 2018;8(3):416-425.

Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, H Cook T, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796.

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.

Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JK, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871-1878.

Curtis BR, Hsu Y-, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood. 2018;131(13):1486-1489.